Compare S&P Global Inc (SPGI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs BIO-TECHNE Corp — how do they compare? S&P Global Inc trades at $431.27 (market cap $132.71B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: S&P Global Inc is far larger — about 11.9× BIO-TECHNE Corp's market cap, and S&P Global Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals.
| SPGI | TECH | |
|---|---|---|
Market Cap | $132.71B | $11.16B |
Sector | Financials | Health |
52-Week High | $534.79 | $72.12 |
52-Week Low | $370.42 | $43.31 |
Enterprise Value | $144.68B | $11.24B |
Dividend Yield | 0.87% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
